© 1999 American Heart Association, Inc.
Original Contributions |
Microalbuminuria and Peripheral Arterial Disease Are Independent Predictors of Cardiovascular and All-Cause Mortality, Especially Among Hypertensive Subjects
Five-year Follow-up of the Hoorn Study
From the Institute for Research in Extramural Medicine (A.J., P.J.K., H.G.R., R.J.H., G.N., J.M.D., L.M.B., C.D.A.S.), Department of Epidemiology and Biostatistics (P.J.K., L.M.B.), and Department of Internal Medicine, Academic Hospital (R.J.H., C.D.A.S.), Vrije Universiteit, Amsterdam, The Netherlands.
Correspondence to Dr Coen D.A. Stehouwer, Department of Internal Medicine, Academic Hospital Vrije Universiteit De Boelelaan 1118, 1007 MB Amsterdam, The Netherlands. E-mail cda.stehouwer{at}azvu.nl
 |
Abstract |
|---|
 Top Abstract IntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Abstract—Microalbuminuria (MA) is associated with increased cardiovascular and all-cause mortality. It has been proposed that MA reflects generalized atherosclerosis and may thus predict mortality. To investigate this hypothesis, we studied the associations between, on the one hand, MA and peripheral arterial disease (PAD), a generally accepted marker of generalized atherosclerosis, and, on the other hand, cardiovascular and all-cause mortality in an age-, sex-, and glucose tolerance-stratified sample (n=631) of a population-based cohort aged 50 to 75 years followed prospectively for 5 years. At baseline, the albumin-to-creatinine ratio (ACR) was measured in an overnight spot urine sample; MA was defined as ACR >2.0 mg/mmol. PAD was defined as an ankle-brachial pressure index below 0.90 and/or a history of a peripheral arterial bypass or amputation. After 5 years of follow-up, 58 subjects had died (24 of cardiovascular causes). Both MA and PAD were associated with a 4-fold increase in cardiovascular mortality. After adjusting for age, sex, diabetes mellitus, hypertension, levels of total and HDL-cholesterol and triglyceride, body mass index, smoking habits, and preexistent ischemic heart disease, the relative risks (RR) (95% confidence intervals) were 3.2 (1.3 to 8.1) for MA and 2.4 (0.9 to 6.1) for PAD. When both MA and PAD were included in the multivariate analysis, the RRs were 2.9 (1.1 to 7.3) for MA and 2.0 (0.7 to 5.7) for PAD. MA and PAD were both associated with an about 2-fold increase in all-cause mortality. The RRs of all-cause mortality associated with MA and PAD were about 4 times higher among hypertensive than among normotensive subjects. We conclude that both MA and PAD are associated with an increased risk of cardiovascular mortality. MA and PAD are mutually independent risk indicators. The associations of MA and PAD with all-cause mortality are somewhat weaker. They are more pronounced in the presence of hypertension than in its absence. These data suggest that MA affects mortality risk through a mechanism different from generalized atherosclerosis.
Key Words: microalbuminuria • peripheral arterial disease • mortality • noninsulin dependent diabetes mellitus • hypertension
|
Introduction |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
The estimation of individual cardiovascular risk over and above the assessment of classic risk factors, such as age, hypercholesterolemia, and hypertension, is an important prerequisite for focusing preventive measures. It has been suggested that the presence of microalbuminuria (MA) and peripheral arterial disease (PAD) can identify subjects at especially high risk.1 2 3 4 5 6 7 8
It is thought that the excess risk associated with MA and PAD cannot be attributed solely to an increased prevalence of conventional risk factors, such as hypertension, smoking, and noninsulin-dependent diabetes mellitus.4 8 9 10 11 12 13 Current hypotheses aiming to explain the association of MA and PAD with incident cardiovascular disease have focused on the possibility that both MA and PAD may be markers of generalized atherosclerosis.14 15 16 17 The evidence for this is stronger for PAD than for MA. An alternative hypothesis is that MA is a marker of a generalized vascular, possibly endothelial, dysfunction that is distinct from atherosclerosis.18
To investigate these issues, we examined, in a prospective cohort study, the relations between MA and PAD on the one hand and cardiovascular and all-cause mortality on the other. We reasoned that, if MA affects risk of mortality through generalized atherosclerosis, the association of MA with mortality would be weakened by adjusting for the presence of PAD, which, as a marker of generalized atherosclerosis, would be an intermediate in the causal pathway linking MA with mortality. If, on the other hand, MA and PAD confer mutually independent excess risks of mortality, this would argue against the idea that MA affects risk through generalized atherosclerosis. In addition, such a finding would have important consequences for individual risk assessment because both measurements would be useful for estimation of cardiovascular risk.
|
Subjects and Methods |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
The study population consisted of an age-, sex-, and glucose tolerance-stratified sample of the Hoorn study, a population-based cohort study of disturbances of glucose tolerance in a white population aged 50 to 75 years conducted from October 1989 until February 1992, as described previously.19 In brief, 2484 white subjects (71% of those invited) participated. All subjects, except previously diagnosed diabetic subjects treated with oral glucose-lowering agents or insulin, underwent an oral glucose tolerance test (OGTT) according to the WHO guidelines.20 Subjects with a 2-hour post-load glucose
7.5 mmol/L, all subjects with
noninsulin-dependent diabetes mellitus (NIDDM), and a random sample of
subjects with a 2-hour post-load glucose <7.5 mmol/L stratified
by age and sex were invited within 4 weeks for a second visit to
investigate glucose intolerance-related complications (709 invited, of
whom 631 (89%) participated). These subjects underwent a second OGTT
(except those who already used blood glucose-lowering agents; n=67). On
the basis of the 2 OGTTs, glucose tolerance was divided into 3
categories20 : normal glucose tolerance (NGT; n=288),
impaired glucose tolerance (IGT; n=170), and NIDDM (n=173). We chose this procedure for reasons of efficiency, because we wished to study a smaller, but still random, sample in more detail. Subjects with NGT, IGT, or NIDDM in the present study population were thus a random sample of all subjects with NGT, IGT, or NIDDM in the initial cohort. The prevalences of NGT, IGT, and NIDDM, and of associated variables, such as microalbuminuria, in the present study population are not the same as in the initial cohort, but because the exact sampling procedure is known, we can back-calculate the prevalences in the initial cohort (n=2484) from those in the second sample (n=631), as previously described in detail.19 21
From these subjects, we obtained an ankle-brachial blood pressure index
(ABPI) (n=631), a resting ECG (ECG) (n=625), and an early-morning,
first-voided spot urine sample to measure the urinary
albumin-to-creatinine ratio (ACR) (n=607). Urinary
albumin was measured by rate nephelometry (Array Protein
System, Beckman) with a threshold of 6.2 mg/L and intra- and interassay
coefficients of variation of 
5% and 8%,
respectively.22 Urinary creatinine was
measured by a modified Jaffé method. Subjects were classified as
having PAD when they had an ABPI <0.9 and/or when they had undergone a
peripheral arterial bypass or amputation. (A
reproducibility test of the Doppler-assisted systolic blood
pressure measurements to obtain the ABPI was performed in a random
sample (n=41), within 6 to 9 months after the first measurement.) The
agreement between the 2 examinations for the criteria of ABPI <0.90,
expressed as kappa, was 0.73 [95% confidence interval (CI) 0.49 to
0.98] indicating good agreement. An ABPI >1.50 (a level possibly
indicating medial arterial calcification23 )
could not be detected in any of the subjects. Subjects were classified
as having preexistent ischemic heart disease (IHD) when they
had an ECG with a Minnesota code 1.1 to 1.3, 4.1 to 4.3, 5.1 to 5.3, or
7.1 and/or had undergone coronary bypass surgery or
angioplasty; as having cerebrovascular disease when they had evidence
of a past transient ischemic attack or stroke according to the
WHO cardiovascular questionnaire24 ; and as
having microalbuminuria (MA) when they had an urinary
albumin concentration greater than the assay threshold (6.2
mg/L; n=336) and an ACR >2.0 mg/mmol. (An overnight ACR
>2.0 mg/mmol has a high sensitivity to detect an albumin
excretion rate >30 µg/min25 ). Of all urine
samples, 32 were excluded because of the use of an
angiotensin-converting enzyme inhibitor. In a
representative sample of 174 subjects, 2 urine
collections were available and the presence of MA for these subjects
was therefore based on the mean ACR of the 2 urine collections.
Blood pressure was calculated as the mean of 4 measurements, performed
on 2 different occasions, using a random-zero sphygmomanometer under
standardized conditions. Hypertension was defined as
diastolic pressure 95 mm Hg, systolic
pressure 160 mm Hg and/or the use of antihypertensive
drugs.26 Data on weight, height, body mass index (BMI),
smoking habits, glycated hemoglobin (HbA1c), fasting specific plasma
insulin, fasting serum creatinine, total
cholesterol, HDL-cholesterol, and
triglyceride levels were obtained.19 21 Low
density lipoprotein-cholesterol was calculated by the
Friedewald formula,27 except when triglyceride
level was >4.55 mmol/L (n=23). The creatinine
clearance was calculated from serum creatinine using the
Cockcroft and Gault formula.28 Normal renal function and
mild and moderate renal failure were defined as creatinine
clearance >80, 51 to 80, and <51 mL/min, respectively. (There were no
subjects with creatinine clearance <24 mL/min.) Smoking
habits were obtained from a standardized questionnaire. Current smoking
was defined as currently smoking cigarettes and/or cigars.
Follow-up Measurements
Data on the subjects' vital status on April 1, 1997 were
collected from the mortality register of the municipality of Hoorn. Of
49 subjects who moved out of town, information on vital status was
obtained from the new local municipalities. For each subject, we
determined whether or not death had occurred in the first 5 years of
follow-up. For all subjects who died, the cause of death was extracted
from the medical records of the general practitioner
and the hospital of Hoorn, verified by 2 physicians and classified
according to the ninth edition of the International
Classification of Diseases. Cardiovascular
mortality was defined as codes 390 to 459, cancer mortality as codes
140 to 240, and sudden death as code 798. Information on cause of death
could not be obtained for 6 (10%) of the deceased subjects.
All participants gave informed consent for this study, which was approved by the local ethics committee.
Statistical Analyses
All analyses were performed with the Statistical
Package for the Social Sciences (SPSS). Survival during 5 years of
follow-up was calculated by Kaplan-Meier curves for different groups
and differences were tested by the logrank test. Predictors of 5-year
cardiovascular and all-cause mortality were determined
by Cox proportional hazards multiple regression analysis, in
all cases—because of the stratification procedure—with adjustment for
age, sex, IGT, and NIDDM. Results are described as relative risks (RRs)
(hazard ratios) with 95% CIs.
Potential risk factors measured on a continuous scale were used as such in the regression models, except for HDL-cholesterol and BMI, because the association of these variables with all-cause mortality was nonlinear. Therefore, a low HDL-cholesterol was defined as a level <0.9 mmol/L29 and obesity as BMI >27 kg/m2 for men and >26 kg/m2 for women.30 Levels of fasting insulin and triglyceride were log-transformed because of a better fit of the regression model. To evaluate a possible effect-modifying role of potential risk factors, Cox regression analyses were performed with the risk factor of interest, MA (or PAD), and their product term in the model. A significant relative risk for the product term was considered as effect modification by that risk factor. To assess whether MA and PAD were independently associated with mortality, regression analyses were primarily adjusted for all risk factors that were statistically significant in initial analyses and secondarily for other potential risk factors of interest which showed no significant association in the initial analyses.
To investigate whether MA and PAD affected risk of mortality through similar pathways, regression analyses were performed that included both MA and PAD as independent variables. Two-sided probability values <0.05 were considered statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Table 1
shows characteristics of the
study population. Of all subjects with MA (n=66), 23% had PAD, whereas
among all subjects with PAD (n=69), 22% had MA. After 5 years of
follow-up, 58 of the 631 subjects had died, of whom 24 (41%) died of
cardiovascular disease. Among NGT subjects, 22% (2/9)
of those with MA died and 18% (4/22) of those with PAD; for IGT
subjects, the rates were 7% (1/14) and 6% (1/17), respectively; and
for NIDDM subjects, 30% (10/33) and 37% (11/30), respectively.
|
Cardiovascular Mortality
Age, hypertension, a low HDL-cholesterol level,
triglyceride level, NIDDM, and preexistent IHD were
significantly associated with cardiovascular mortality
after adjusting for age, gender, IGT, and NIDDM (Table 2). In the entire group, MA and PAD were
both associated with about 4-fold increased risk of
cardiovascular death after adjusting for age, gender,
IGT, and NIDDM (Table 3; Figure 1a and 1b). After further adjustment for
hypertension, low level of HDL-cholesterol,
triglyceride level, and preexistent IHD, the RRs associated
with MA and PAD were 3.3 and 3.6, respectively (Table 3). After
additional adjustment for current smoking, obesity, and total
cholesterol level, the RR of MA was similar and the RR of
PAD decreased to 2.4 (Table 3; models 1 to 3).
|
|
|
Further analyses were aimed at investigating whether
cardiovascular mortality risks associated with MA and
PAD were independent of each other. Mutual adjustment of MA and PAD did
not materially change the RR for cardiovascular
mortality, even after adjusting for other risk factors (Table 3
,
models 4 to 6). The risk of cardiovascular mortality
showed around 13-fold (2.98x4.31; Table 3) increase if both MA
and PAD were present compared with absent (Figure 2).
|
Age, obesity, current smoking, hypertension, levels of total and
HDL-cholesterol and triglyceride, NIDDM, and
preexistent IHD showed no significant interaction with MA or PAD (all
P>0.2, data not shown). Subgroup analyses in
nondiabetic and diabetic subjects separately showed higher RRs
associated with MA and PAD among diabetic compared with nondiabetic
subjects (Table 3). In a forward stepwise regression model,
including all variables shown in Table 2, age, current
smoking, low level of HDL-cholesterol, NIDDM, preexistent
IHD, and MA were significantly associated with
cardiovascular mortality (Table 4).
|
Four subjects died of sudden death. When sudden death was enclosed in
the definition, the RRs of cardiovascular mortality
were 3.66 (1.59 to 8.39) for MA and 3.52 (1.52 to 7.72) for PAD in
analyses similar to model 1 in Table 3.
Inclusion of serum creatinine or creatinine clearance (Ccr) calculated from the Cockroft and Gault formula28 in the analyses above slightly decreased the RRs for MA and PAD. Further analyses showed that this was entirely due to subjects with moderate renal failure (Ccr<51 mL/min; n=22); after exclusion of these subjects, the respective RRs were similar to those in the initial analyses (data not shown).
All-Cause mortality
MA and PAD were both associated with an about 2-fold increased
risk of all-cause mortality after adjusting for age, gender, IGT, and
NIDDM (Table 5). Further adjustment for
current smoking, low level of HDL-cholesterol, level of
triglyceride, and preexistent IHD slightly decreased the
RRs associated with MA and PAD (to 1.85 and 1.64, respectively). These
RRs were similar after further adjustment for obesity, hypertension,
and total cholesterol level (Table 5). Additional
analyses indicated that the risk estimates for MA and PAD were
markedly (about 5- and 4-fold) higher in the presence of hypertension
than in its absence (P for interaction=0.15 and 0.08,
respectively; Table 5). The RR of mortality associated with MA
among hypertensive nondiabetic subjects (n=150) was 2.63 (0.64 to
10.83) in an analysis analogous to model 1 in Table 5.
Age, obesity, current smoking, level of total and
HDL-cholesterol and triglyceride, NIDDM, and
preexisting IHD showed no interaction with MA or PAD with regard to
risk of mortality (data not shown).
|
The RRs associated with MA and PAD, after adjusting for age, gender, IGT, and NIDDM, were not importantly affected by mutual adjustment; both remained about 2.0 (data not shown). After further adjustment for current smoking, low level of HDL-cholesterol, triglyceride level, and preexistent IHD, the RRs (95% CIs) were 1.73 (0.89 to 3.38) for MA and 1.46 (0.73 to 2.91) for PAD. These RRs were similar after further adjustment for obesity, hypertension, and total cholesterol level (data not shown).
Inclusion of serum creatinine or creatinine clearance (Ccr) calculated from the Cockroft and Gault formula28 in the analyses above slightly decreased the RRs for MA and PAD. Further analyses showed that this was entirely due to subjects with moderate renal failure (Ccr<51 mL/min; n=22); after exclusion of these subjects, the respective RRs were similar to those in the initial analyses (data not shown).
Twenty-six subjects (45%) died of cancer. Neither MA nor PAD were significantly associated with cancer mortality [RRs 0.96 (0.28 to 3.27) and 1.05 (0.36 to 3.07), respectively].
Finally, we examined whether changing the definitions of PAD and MA would affect our results. Lowering the ABPI criterion from 0.9 to 0.8 or 0.7 did not materially affect the results (data not shown). MA defined as ACR >3.0 mg/mmol somewhat increased the RRs among diabetic subjects: for example, the RR for all-cause mortality adjusted for age and sex was 3.01 (1.34 to 6.75) versus 2.22 (1.01 to 4.87) when MA was defined as ACR >2.0 mg/mmol. Other risk estimates showed only minor changes (data not shown). Excluding subjects with macroalbuminuria (ACR >30 mg/mmol; n=6) gave similar results (data not shown). When MA was defined on the basis of 1 overnight urine sample in all subjects, the results were also similar (data not shown). Other definitions of a low HDL-cholesterol and obesity also gave similar results.
|
Discussion |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
This study shows that both MA and PAD are strongly associated with 5-year risk of cardiovascular death. Mutual adjustment did not markedly affect the relative risk estimates, which argues against the idea that MA is a marker of generalized atherosclerosis. Both MA and PAD are useful measurements in estimating individual cardiovascular risk, irrespective of the presence of IHD. In addition, our data suggest that MA and PAD are particularly strong risk indicators among subjects with hypertension.
Our study confirms that MA and PAD are strong indicators of an increased risk of cardiovascular mortality, independent of the presence of important cardiovascular risk factors such as hypercholesterolemia, smoking, and hypertension.1 2 3 4 5 6 7 8 PAD is thought to be a marker of generalized atherosclerotic disease, which is a plausible explanation for the increased risk of mortality in subjects with PAD.14 15 16 In contrast, it is unclear why MA is associated with an increased mortality risk.1 2 4 6 8 It has been suggested that MA, like PAD, is a marker of generalized atherosclerosis.31 32 33 34 35 36 Two findings of the present study argue against this idea. First, only about 25% of subjects with MA also had PAD and vice versa. Second, the increased risk of mortality conferred by the presence of MA was not materially lowered by including PAD in the multivariate regression model, which would have been expected if MA affected risk through generalized atherosclerosis.
How, then, can the association between MA and mortality be explained? First, MA is associated with increased levels of von Willebrand factor, thrombomodulin, fibrinogen, thrombin–antithrombin III complexes and impaired fibrinolytic activity and may thus be a marker of a prothrombotic state.37 38 39 Second, MA may reflect a specific type of endothelial dysfunction18 40 distinct from atherosclerosis per se. Finally, MA in part may be a marker of a low-grade chronic inflammatory state,41 which itself is associated with an increased risk of cardiovascular disease.42 43 Taken together, these data and the present study support the hypothesis that MA and PAD affect risk through different pathways. Further studies are needed to address the mechanisms by which MA increases the risk of cardiovascular disease in more detail.
We found that both MA and PAD were associated more strongly with
all-cause mortality among hypertensive than among normotensive subjects
(Table 5), although the confidence intervals of the risk
estimates clearly do not exclude the possibility of significant
associations of MA and PAD with mortality among normotensive subjects.
In previous studies, the mortality risk associated with MA or PAD has
usually been adjusted for the presence of
hypertension1 2 4 or systolic or
diastolic blood pressure.3 5 8 However, this
does not necessarily rule out the presence of an interaction with
hypertension, as suggested by our results. The explanation for these
findings is not clear, but it is noteworthy that, in the same
population, we found the presence of hypertension (and NIDDM) to be the
strongest determinants of MA.22 This, together with the
present results, raises the possibility that, in the presence of
hypertension, the pathogenetic backgrounds of MA and PAD and of their
link with mortality are distinct from those in the absence of
hypertension. These issues require further investigation.
MA was thus significantly associated with all-cause mortality among hypertensive subjects, which is in agreement with some,44 45 but not all34 previous studies, whereas other studies2 4 6 8 did not specifically examine this issue. This result, however, has to be interpreted with caution, because our study was not specifically designed to answer this question and lacked information about duration and type of hypertension. Nevertheless, our data add to accumulating evidence that, among hypertensive subjects, both overt proteinuria46 47 and MA44 45 may be markers of a poor prognosis.
The clinical implication of our findings is that both measurement
of the ankle-brachial blood pressure index and of the urinary
albumin excretion is useful to estimate individual risk (Tables 3 to 5). Both measurements are easy to obtain. All-cause
and cardiovascular mortality risk are increased about
3-fold and 15-fold, respectively, when both PAD and MA are present,
compared with when both are absent (Figure 2). It is especially
noteworthy that the association of MA with
cardiovascular mortality is of the same order of
magnitude as those of NIDDM and preexistent ischemic heart
disease (Table 4).
Our study had several limitations. In the majority of subjects,
MA was estimated from 1 urine sample, which may have increased
nondifferential misclassification, leading to an underestimation of the
association with mortality. The study was too small to establish
definitively whether MA and PAD are significantly stronger risk markers
in hypertensive than in normotensive subjects. The study was also too
small to investigate whether the increased mortality risk associated
with MA among hypertensive subjects varied with the mode of treatment
of hypertension or its duration, or with the level of blood pressure.
Although we found evidence against the concept that MA is a marker of
generalized atherosclerosis, we did not address
alternative mechanisms linking MA to mortality. Finally, our study
lacked the power to exclude with confidence the presence of interaction
between glucose tolerance status and MA (or PAD) with respect to
cardiovascular mortality. Both MA and PAD were in fact
more strongly associated with cardiovascular mortality
in diabetic than in nondiabetic subjects, although this was not
significant (Table 3). However, it appears unlikely that such an
interaction, if present, would affect our main conclusion, ie, that
MA and PAD are mutually independent risk indicators.
In conclusion, we have shown that both MA and PAD are
independently associated with cardiovascular mortality
and so may affect risk through different pathways. Measurement of the
urinary albumin excretion and the ankle-brachial pressure index
are therefore useful to estimate individual risk (Figure 2 and
Table 4). Such information is clinically useful, because it can
help to individualize decisions on, for example,
cholesterol- and blood pressure-lowering treatment.
Furthermore, the associations of MA and PAD with mortality seem more
pronounced in hypertensive than in normotensive subjects. Further
studies are needed to clarify the underlying pathophysiologic mechanism
linking MA to (cardiovascular) mortality, as this may
have additional therapeutic implications.
|
Acknowledgments |
|---|
This study was supported by a Clinical Research Fellowship from the Diabetes Fonds Nederland and the Netherlands Organization for Scientific Research (NWO). We are indebted to Prof J. S. Yudkin for critically reading our manuscript and for his thoughtful comments.
Received June 15, 1998; accepted August 18, 1998.
|
References |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
1. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet. 1988;2:530–533.[Medline] [Order article via Infotrieve]
2. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ. 1990;300:297–300.
3. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–386.[Abstract]
4. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes. 1992;41:736–741.[Abstract]
5.
Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB.
Decreased ankle/arm blood pressure index and mortality in elderly
women. JAMA. 1993;270:465–469.
6. Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care. 1993;16:996–1003.[Abstract]
7.
Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E,
Ruckley CV. Use of ankle brachial pressure index to predict
cardiovascular events and death: a cohort study.
BMJ. 1996;313:1440–1444.
8. Beilin J, Stanton KG, McCann VJ, Knuiman MW, Divitini ML. Microalbuminuria in type 2 diabetes: an independent predictor of cardiovascular mortality. Aust N Z Journal of Medicine. 1996;26:519–525.
9. Mattock MB, Keen H, Viberti GC, El-Gohari MR, Murrells TJ, Scott GS, Wing JR, Jackson PG. Coronary heart disease and urinary albumin excretion rate in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1988;31:82–87.[Medline] [Order article via Infotrieve]
10. Gall MA, Rossing P, Skott P, Hougaard P, Nielsen FS, Parving H-H. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1991;34:655–661.[Medline] [Order article via Infotrieve]
11. Fitzgerald AP, Jarrett RJ. Are conventional risk factors for mortality relevant in type 2 diabetes? Diabet Med. 1991;8:475–480.[Medline] [Order article via Infotrieve]
12. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Eight to nine year mortality in known non-insulin dependent diabetics and controls. Kidney Int. 1992;41:731–735.[Medline] [Order article via Infotrieve]
13. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis. 1991;87:119–128.[Medline] [Order article via Infotrieve]
14. Hertzer NR, Beven EG, Young JR, O'Hara PJ, Ruschhaupt WF, Graor RA, DeWolfe VG, Maljovec LL. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg. 1984;199:223–233.[Medline] [Order article via Infotrieve]
15. Klop RB, Eikelboom BC, Taks AC. Screening of the internal carotid arteries in patients with peripheral vascular disease by colour-flow duplex scanning. Eur J Vasc Surg. 1991;5:41–45.[Medline] [Order article via Infotrieve]
16. Missouris CG, Buckenham T, Cappuccio FP, MacGregor GA. Renal artery stenosis: a common and important problem in patients with peripheral vascular disease. Am J Med. 1994;96:10–14.[Medline] [Order article via Infotrieve]
17. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia.. 1989;32:219–226.[Medline] [Order article via Infotrieve]
18. Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHL, Donker AJM, den Ottolander GJH. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992;340:319–323.[Medline] [Order article via Infotrieve]
19. Beks PJ, Mackaay AJ, de Neeling JN, de Vries H, Bouter LM, Heine RJ. Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: the Hoorn Study. Diabetologia. 1995;38:86–96.[Medline] [Order article via Infotrieve]
20. World Health Organization Study Group on Diabetes Mellitus. Technical Report Series No 727, WHO, Geneva. 1985.
21.
Hoogeveen EK, Kostense PJ, MacKaay AJ, Jacobs C, Bouter
LM, Heine RJ, Stehouwer CDA. Hyperhomocysteinemia is associated with an
increased risk of cardiovascular disease, especially in
non-insulin-dependent diabetes mellitus: a population based study.
Arterioscler Thromb Vasc Biol. 1998;18:133–138.
22. Jager A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA. Microalbuminuria is strongly associated with non-insulin dependent diabetes mellitus and hypertension, but not with the insulin resistance syndrome: the Hoorn Study. Diabetologia. 1998;41:694–700.[Medline] [Order article via Infotrieve]
23.
Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP,
Borhani NO, Wolfson SK. Ankle-arm index as a marker of
atherosclerosis in the Cardiovascular
Health Study. Circulation. 1993;88:837–845.
24. Rose GA. Blackburn H. World Health Organ Monogr Ser.. 1968;56:1–188.
25. Gatling W, Knight C, Mullee MA, Hill RD. Microalbuminuria in diabetes: a population study of the prevalence and an assessment of three screening tests. Diabet Med. 1988;5:343–7.[Medline] [Order article via Infotrieve]
26. Arterial hypertension. Report of a WHO expert committee. World Health Organ Tech Rep Ser. 1978:7–56.
27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.[Abstract]
28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.[Medline] [Order article via Infotrieve]
29. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1333–1445.[Medline] [Order article via Infotrieve]
30. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416–422.[Medline] [Order article via Infotrieve]
31. Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci (Colch). 1995;88:629–33.[Medline] [Order article via Infotrieve]
32. Pontremoli R, Sofia A, Tirotta A, Ravera M, Nicolella C, Viazzi F, Magnasco A, Del Sette M, Martinoli C, Deferrari G. Microalbuminuria is associated with a worse cardiovascular risk profile and target organ damage in essential hypertension. Contrib Nephrol.. 1996;119:115–120.[Medline] [Order article via Infotrieve]
33.
Mykkänen L, Zaccaro DJ, O'Leary DH, Howard G,
Robbins DC, Haffner SM. Microalbuminuria and carotid artery
intima-media thickness in nondiabetic and NIDDM subjects. The Insulin
Resistance Atherosclerosis Study (IRAS).
Stroke. 1997;28:1710–1716.
34. Agewall S, Wikstrand J, Ljungman S, Herlitz H, Fagerberg B. Does microalbuminuria predict cardiovascular events in nondiabetic men with treated hypertension? Risk Factor Intervention Study Group. Am J Hypertens. 1995;8:337–342.[Medline] [Order article via Infotrieve]
35. Bigazzi R, Bianchi S, Nenci R, Baldari D, Baldari G, Campese VM. Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J Hum Hypertens. 1995;9:827–833.[Medline] [Order article via Infotrieve]
36.
Kuusisto J, Mykkänen L, Pyörälä
K, Laakso M. Hyperinsulinemic
microalbuminuria. A new risk indicator for coronary
heart disease. Circulation. 1995;91:831–837.
37. Gruden G, Cavallo-Perin P, Bazzan M, Stella S, Vuolo A, Pagano G. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria. Diabetes. 1994;43:426–429.[Abstract]
38.
Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T,
Miyata T. Activation of tissue factor-induced coagulation and
endothelial cell dysfunction in non-insulin-dependent
diabetic patients with microalbuminuria. Arterioscler
Thromb Vasc Biol. 1995;15:1114–1120.
39. Stehouwer CDA. Von Willebrand factor, dysfunction of the vascular endothelium, and the development of renal and vascular complication in diabetes. In Mogensen CE, ed. The Kidney and Hypertension in Diabetes Mellitus. Dordrecht: Kluwer Academic Publishers; 1997:155–163.
40. Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell'Omo G, Catapano G, Matteucci E, Talarico L, Mozale M, DeNegri F. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 1994;344:14–18.[Medline] [Order article via Infotrieve]
41. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. Insulin resistance syndrome and endothelial damage: role of adipose tissue derived proinflammatory cytokines [Abstract]. Diabetologia. 1997;40:A305(1200).
42.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens
CH. Inflammation, aspirin, and the risk of
cardiovascular disease in apparently healthy men.
N Engl J Med. 1997;336:973–979.
43. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462–466.[Medline] [Order article via Infotrieve]
44. Agewall S, Wikstrand J, Ljungman S, Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group. Am J Cardiol. 1997;80:164–169.[Medline] [Order article via Infotrieve]
45. Ljungman S, Wikstrand J, Hartford M, Berglund G. Urinary albumin excretion—a predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Am J Hypertens. 1996;9:770–778.[Medline] [Order article via Infotrieve]
46. Bulpitt CJ, Beilin LJ, Clifton P, Coles EC, Dollery CT, Gear JSS, Harper GS, Johnson BF. Risk factors for death in treated hypertensive patients. Report from the D.H.S.S. Hypertension Care Computing Project. Lancet. 1979;2:134–137.[Medline] [Order article via Infotrieve]
47. Samuelsson O, Wilhelmsen L, Elmfeldt D, Pennert K, Wedel H, Wikstrand J, Berglund G. Predictors of cardiovascular morbidity in treated hypertension: results from the primary preventive trial in Goteborg, Sweden. J Hypertens. 1985;3:167–176.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  A. H. Brantsma, S. J. L. Bakker, H. L. Hillege, D. de Zeeuw, P. E. de Jong, R. T. Gansevoort, and for the PREVEND Study Group Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion Nephrol. Dial. Transplant., December 1, 2008; 23(12): 3851 - 3858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Criqui, J. K. Ninomiya, D. L. Wingard, M. Ji, and A. Fronek Progression of Peripheral Arterial Disease Predicts Cardiovascular Disease Morbidity and Mortality J. Am. Coll. Cardiol., November 18, 2008; 52(21): 1736 - 1742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. He, K. Liu, M. L Daviglus, E. Mayer-Davis, N. S. Jenny, R. Jiang, P. Ouyang, L. M Steffen, D. Siscovick, C. Wu, et al. Intakes of long-chain n-3 polyunsaturated fatty acids and fish in relation to measurements of subclinical atherosclerosis Am. J. Clinical Nutrition, October 1, 2008; 88(4): 1111 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Ankle Brachial Index Collaboration Ankle Brachial Index Combined With Framingham Risk Score to Predict Cardiovascular Events and Mortality: A Meta-analysis JAMA, July 9, 2008; 300(2): 197 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Rademacher, M. Mauer, D. R. Jacobs Jr, B. Chavers, J. Steinke, and A. Sinaiko Albumin Excretion Rate in Normal Adolescents: Relation to Insulin Resistance and Cardiovascular Risk Factors and Comparisons to Type 1 Diabetes Mellitus Patients Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 998 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Danziger Importance of Low-Grade Albuminuria Mayo Clin. Proc., July 1, 2008; 83(7): 806 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Basi, P. Fesler, A. Mimran, and J. B. Lewis Microalbuminuria in Type 2 Diabetes and Hypertension: A marker, treatment target, or innocent bystander? Diabetes Care, February 1, 2008; 31(Supplement_2): S194 - S201. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sheehan, S.-W. Tsaih, B. L. King, C. Stanton, G. A. Churchill, B. Paigen, and K. DiPetrillo Genetic analysis of albuminuria in a cross between C57BL/6J and DBA/2J mice Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1649 - F1656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Daly Is early chronic kidney disease an important risk factor for cardiovascular disease?: A Background Paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_9): ix19 - ix25. [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]
|
|
|
|
|
|
M. R. Weir Microalbuminuria and Cardiovascular Disease Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 581 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Mostaza, C. Suarez, L. Manzano, M. Cairols, F. Garcia-Iglesias, J. Sanchez-Alvarez, J. Ampuero, D. Godoy, A. Rodriguez-Samaniego, M. A. Sanchez-Zamorano, et al. Relationship between Ankle-Brachial Index and Chronic Kidney Disease in Hypertensive Patients with No Known Cardiovascular Disease J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S201 - S205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Redon, F. Morales-Olivas, A. Galgo, M. A. Brito, J. Mediavilla, R. Marin, P. Rodriguez, S. Tranche, J. V. Lozano, C. Filozof, et al. Urinary Albumin Excretion and Glomerular Filtration Rate across the Spectrum of Glucose Abnormalities in Essential Hypertension J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S236 - S245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D.A. Stehouwer and Y. M. Smulders Microalbuminuria and Risk for Cardiovascular Disease: Analysis of Potential Mechanisms J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2106 - 2111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fukuhara and K. Hida Pulsatility index at the cervical internal carotid artery as a parameter of microangiopathy in patients with type 2 diabetes. J. Ultrasound Med., May 1, 2006; 25(5): 599 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. de Jager, J. M. Dekker, A. Kooy, P. J. Kostense, G. Nijpels, R. J. Heine, L. M. Bouter, and C. D.A. Stehouwer Endothelial Dysfunction and Low-Grade Inflammation Explain Much of the Excess Cardiovascular Mortality in Individuals With Type 2 Diabetes: The Hoorn Study Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 1086 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Segura, J. A. Garcia-Donaire, M. Praga, and L. M. Ruilope Chronic Kidney Disease as a Situation of High Added Risk in Hypertensive Patients J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S136 - S140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Stam, C. van Guldener, A. Becker, J. M. Dekker, R. J. Heine, L. M. Bouter, and C. D.A. Stehouwer Endothelial Dysfunction Contributes to Renal Function-Associated Cardiovascular Mortality in a Population with Mild Renal Insufficiency: The Hoorn Study J. Am. Soc. Nephrol., February 1, 2006; 17(2): 537 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Montalescot and J.-P. Collet Preserving cardiac function in the hypertensive patient: why renal parameters hold the key Eur. Heart J., December 2, 2005; 26(24): 2616 - 2622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Xu, E. T Lee, L. G Best, M. Begum, W. C Knowler, R. R Fabsitz, and B. V Howard Association of albuminuria with all-cause and cardiovascular disease mortality in diabetes: the Strong Heart Study The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 334 - 340. [Abstract] [PDF]
|
|
|
|
 |
|
 J. M. Dekker, C. Girman, T. Rhodes, G. Nijpels, C. D.A. Stehouwer, L. M. Bouter, and R. J. Heine Metabolic Syndrome and 10-Year Cardiovascular Disease Risk in the Hoorn Study Circulation, August 2, 2005; 112(5): 666 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Redon Urinary Albumin Excretion: Lowering the Threshold of Risk in Hypertension Hypertension, July 1, 2005; 46(1): 19 - 20. [Full Text] [PDF]
|
|
|
|
|
|
K. P. Klausen, H. Scharling, G. Jensen, and J. S. Jensen New Definition of Microalbuminuria in Hypertensive Subjects: Association With Incident Coronary Heart Disease and Death Hypertension, July 1, 2005; 46(1): 33 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. van Hecke, J. M. Dekker, C. D.A. Stehouwer, B. C.P. Polak, J. H. Fuller, A. K. Sjolie, A. Kofinis, R. Rottiers, M. Porta, and N. Chaturvedi Diabetic Retinopathy Is Associated With Mortality and Cardiovascular Disease Incidence: The EURODIAB Prospective Complications Study Diabetes Care, June 1, 2005; 28(6): 1383 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Pascual, E. Rodilla, C. Gonzalez, S. Perez-Hoyos, and J. Redon Long-Term Impact of Systolic Blood Pressure and Glycemia on the Development of Microalbuminuria in Essential Hypertension Hypertension, June 1, 2005; 45(6): 1125 - 1130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508. [Full Text] [PDF]
|
|
|
|
|
|
F. Viazzi, G. Leoncini, D. Parodi, E. Ratto, S. Vettoretti, V. Vaccaro, A. Parodi, V. Falqui, C. Tomolillo, G. Deferrari, et al. Impact of Target Organ Damage Assessment in the Evaluation of Global Risk in Patients with Essential Hypertension J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S89 - S91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Furtner, S. Kiechl, A. Mair, K. Seppi, S. Weger, F. Oberhollenzer, W. Poewe, and J. Willeit Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population Eur. Heart J., February 1, 2005; 26(3): 279 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kramer, R. Toto, R. Peshock, R. Cooper, and R. Victor Association between Chronic Kidney Disease and Coronary Artery Calcification: The Dallas Heart Study J. Am. Soc. Nephrol., February 1, 2005; 16(2): 507 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ibsen, M. H. Olsen, K. Wachtell, K. Borch-Johnsen, L. H. Lindholm, C. E. Mogensen, B. Dahlof, R. B. Devereux, U. de Faire, F. Fyhrquist, et al. Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study Hypertension, February 1, 2005; 45(2): 198 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Dyer, P. Greenland, P. Elliott, M. L. Daviglus, G. Claeys, H. Kesteloot, H. Ueshima, J. Stamler, and for the INTERMAP Research Group Evaluation of Measures of Urinary Albumin Excretion in Epidemiologic Studies Am. J. Epidemiol., December 1, 2004; 160(11): 1122 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Sowers Treatment of Hypertension in Patients With Diabetes Arch Intern Med, September 27, 2004; 164(17): 1850 - 1857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Korstanje and K. DiPetrillo Unraveling the genetics of chronic kidney disease using animal models Am J Physiol Renal Physiol, September 1, 2004; 287(3): F347 - F352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Dyer, P. Greenland, P. Elliott, M. L. Daviglus, G. Claeys, H. Kesteloot, Q. Chan, H. Ueshima, and J. Stamler Estimating Laboratory Precision of Urinary Albumin Excretion and Other Urinary Measures in the International Study on Macronutrients and Blood Pressure Am. J. Epidemiol., August 1, 2004; 160(3): 287 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Klausen, K. Borch-Johnsen, B. Feldt-Rasmussen, G. Jensen, P. Clausen, H. Scharling, M. Appleyard, and J. S. Jensen Very Low Levels of Microalbuminuria Are Associated With Increased Risk of Coronary Heart Disease and Death Independently of Renal Function, Hypertension, and Diabetes Circulation, July 6, 2004; 110(1): 32 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Jensen, B. Feldt-Rasmussen, K. S. Jensen, P. Clausen, H. Scharling, and B. G. Nordestgaard Transendothelial lipoprotein exchange and microalbuminuria Cardiovasc Res, July 1, 2004; 63(1): 149 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. A. Stehouwer Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease Nephrol. Dial. Transplant., April 1, 2004; 19(4): 778 - 781. [Full Text] [PDF]
|
|
|
|
|
|
M. F. Yuyun, K.-T. Khaw, R. Luben, A. Welch, S. Bingham, N. E. Day, and N. J. Wareham A Prospective Study of Microalbuminuria and Incident Coronary Heart Disease and Its Prognostic Significance in a British Population: The EPIC-Norfolk Study Am. J. Epidemiol., February 1, 2004; 159(3): 284 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F Yuyun, K.-T. Khaw, R. Luben, A. Welch, S. Bingham, N. E Day, and N. J Wareham Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study Int. J. Epidemiol., February 1, 2004; 33(1): 189 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Wachtell, H. Ibsen, M. H. Olsen, K. Borch-Johnsen, L. H. Lindholm, C. E. Mogensen, B. Dahlof, R. B. Devereux, G. Beevers, U. de Faire, et al. Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study Ann Intern Med, December 2, 2003; 139(11): 901 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Romundstad, J. Holmen, H. Hallan, K. Kvenild, and H. Ellekjaer Microalbuminuria and All-Cause Mortality in Treated Hypertensive Individuals: Does Sex Matter?: The Nord-Trondelag Health Study (HUNT), Norway Circulation, December 2, 2003; 108(22): 2783 - 2789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Hypertension, November 1, 2003; 42(5): 1050 - 1065. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation, October 28, 2003; 108(17): 2154 - 2169. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Murtaugh, D. R. Jacobs Jr., X. Yu, M. D. Gross, and M. Steffes Correlates of Urinary Albumin Excretion in Young Adult Blacks and Whites: The Coronary Artery Risk Development in Young Adults Study Am. J. Epidemiol., October 1, 2003; 158(7): 676 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Murabito, J. C. Evans, M. G. Larson, K. Nieto, D. Levy, and P. W. F. Wilson The Ankle-Brachial Index in the Elderly and Risk of Stroke, Coronary Disease, and Death: The Framingham Study Arch Intern Med, September 8, 2003; 163(16): 1939 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Leoncini, F. Viazzi, D. Parodi, S. Vettoretti, E. Ratto, M. Ravera, C. Tomolillo, M. Del Sette, G. P. Bezante, G. Deferrari, et al. Mild Renal Dysfunction and Subclinical Cardiovascular Damage in Primary Hypertension Hypertension, July 1, 2003; 42(1): 14 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T Hirsch and A. M Gotto Jr Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction Vascular Medicine, November 1, 2002; 7(4): 323 - 331. [Abstract] [PDF]
|
|
|
|
|
|
R. Pontremoli, G. Leoncini, M. Ravera, F. Viazzi, S. Vettoretti, E. Ratto, D. Parodi, C. Tomolillo, and G. Deferrari Microalbuminuria, Cardiovascular, and Renal Risk in Primary Hypertension J. Am. Soc. Nephrol., November 1, 2002; 13(90003): S169 - 172. [Abstract] [Full Text]
|
|
|
|
|
|
H. L. Hillege, V. Fidler, G. F.H. Diercks, W. H. van Gilst, D. de Zeeuw, D. J. van Veldhuisen, R. O.B. Gans, W. M.T. Janssen, D. E. Grobbee, P. E. de Jong, et al. Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population Circulation, October 1, 2002; 106(14): 1777 - 1782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D.A. Stehouwer, M.-A. Gall, J. W.R. Twisk, E. Knudsen, J. J. Emeis, and H.-H. Parving Increased Urinary Albumin Excretion, Endothelial Dysfunction, and Chronic Low-Grade Inflammation in Type 2 Diabetes: Progressive, Interrelated, and Independently Associated With Risk of Death Diabetes, April 1, 2002; 51(4): 1157 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jager, V. W.M. van Hinsbergh, P. J. Kostense, J. J. Emeis, G. Nijpels, J. M. Dekker, R. J. Heine, L. M. Bouter, and C. D.A. Stehouwer C-Reactive Protein and Soluble Vascular Cell Adhesion Molecule-1 Are Associated With Elevated Urinary Albumin Excretion but Do Not Explain Its Link With Cardiovascular Risk Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 593 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Redon, E. Rovira, A. Miralles, R. Julve, and J. M. Pascual Factors Related to the Occurrence of Microalbuminuria During Antihypertensive Treatment in Essential Hypertension Hypertension, March 1, 2002; 39(3): 794 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pedrinelli, G. Dell'Omo, G. Penno, and M. Mariani Non-diabetic microalbuminuria, endothelial dysfunction and cardiovascular disease Vascular Medicine, November 1, 2001; 6(4): 257 - 264. [Abstract] [PDF]
|
|
|
|
|
|
R. C.P. Go, R. Desmond, J. M. Roseman, D. S.H. Bell, C. Vanichanan, and R. T. Acton Prevalence and Risk Factors of Microalbuminuria in a Cohort of African-American Women With Gestational Diabetes Diabetes Care, October 1, 2001; 24(10): 1764 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Gerstein, J. F. E. Mann, Q. Yi, B. Zinman, S. F. Dinneen, B. Hoogwerf, J. P. Halle, J. Young, A. Rashkow, C. Joyce, et al. Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals JAMA, July 25, 2001; 286(4): 421 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Roest, J. D. Banga, W. M. T. Janssen, D. E. Grobbee, J. J. Sixma, P. E. de Jong, D. de Zeeuw, and Y. T. van der Schouw Excessive Urinary Albumin Levels Are Associated With Future Cardiovascular Mortality in Postmenopausal Women Circulation, June 26, 2001; 103(25): 3057 - 3061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jager, V. W. M. van Hinsbergh, P. J. Kostense, J. J. Emeis, G. Nijpels, J. M. Dekker, R. J. Heine, L. M. Bouter, and C. D. A. Stehouwer Prognostic implications of retinopathy and a high plasma von Willebrand factor concentration in type 2 diabetic subjects with microalbuminuria Nephrol. Dial. Transplant., March 1, 2001; 16(3): 529 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jager, P. J. Kostense, G. Nijpels, J. M. Dekker, R. J. Heine, L. M. Bouter, A. J. M. Donker, and C. D. A. Stehouwer Serum Homocysteine Levels Are Associated With the Development of (Micro)albuminuria : The Hoorn Study Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 74 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.C. Viberti and S.M. Thomas Searching for new coronary heart disease risk factors Eur. Heart J., December 1, 2000; 21(23): 1905 - 1906. [PDF]
|
|
|
|
 |
|
 P R J Ames, C Tommasino, J Alves, J D Morrow, L Iannaccone, G Fossati, S Caruso, F Caccavo, and V Brancaccio Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study Lupus, November 1, 2000; 9(9): 688 - 695. [Abstract] [PDF]
|
|
|
|
|
|
J. S. Jensen, B. Feldt-Rasmussen, S. Strandgaard, M. Schroll, and K. Borch-Johnsen Arterial Hypertension, Microalbuminuria, and Risk of Ischemic Heart Disease Hypertension, April 1, 2000; 35(4): 898 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pedrinelli, G. Dell'Omo, G. Penno, S. Bandinelli, A. Bertini, V. Di Bello, and M. Mariani Microalbuminuria and Pulse Pressure in Hypertensive and Atherosclerotic Men Hypertension, January 1, 2000; 35(1): 48 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kario, S. Hoshide, K. Shimada, T. G. Pickering, R. S. Khattar, R. Senior, and A. Lahiri White-Coat Hypertension Versus Sustained Hypertension in Japan • Response • Response Circulation, December 21, 1999; 100 (25): e157 - e158. [Full Text] [PDF]
|
|
|
|
|
|
A. Jager, V. W. M. van Hinsbergh, P. J. Kostense, J. J. Emeis, J. S. Yudkin, G. Nijpels, J. M. Dekker, R. J. Heine, L. M. Bouter, and C. D. A. Stehouwer von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects : The Hoorn Study Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 3071 - 3078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jager, V. W.M. van Hinsbergh, P. J. Kostense, J. J. Emeis, G. Nijpels, J. M. Dekker, R. J. Heine, L. M. Bouter, and C. D.A. Stehouwer C-Reactive Protein and Soluble Vascular Cell Adhesion Molecule-1 Are Associated With Elevated Urinary Albumin Excretion but Do Not Explain Its Link With Cardiovascular Risk Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 593 - 598. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||